Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Intermittent Rifabutin and Efavirenz in HIV/TB
NCT00023413Phase 2Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Nov 1999
- Primary completion
- Feb 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of rifabutin in Tuberculosis (TB), sponsored by Centers for Disease Control and Prevention. Primary endpoint: Pharmacokinetics of Rifabutin. Started Nov 1999; status: completed.
02
Drugs
rifabutin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT00023413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00023413.